Global Pfizer CEO Albert Bourla is the pharma executive with the biggest impact on social media, according to a new study. While busy industry leaders may not currently place social media engagement at the top of their priority lists, the study – published by specialist digital insights consultancy, Creation Healthcare –…

USA With office occupation rates on the slide and the life sciences industry’s demand for lab space on the rise, the repurposing of existing offices into medical laboratories has become an important new asset class, writes Liz Chen, a lab planner at HGA Life Science + Advanced Technology Group’s San Diego…

Americas Writing in the August edition of DIA’s Global Forum magazine, Silvia B. Bendiner of WESSX Inc. and Belkis Romeu call for greater regulatory collaboration between Latin American countries, building on an initiative created by Dr. Rafael Pérez Cristiá at the Cuban Regulatory Authority (CECMED).   The need for further regulatory…

Mexico The latest from Mexican pharma, including the distribution agreement between Dow and Azelis, Neuraxpharm’s new LatAm subsidiaries in Mexico and Brazil; Landsteiner Scientific’s restructure, and Merck’s plant expansion in Naucalpan.   Dow and Azelis México, distribution partners for the pharmaceutical market (T21, in Spanish) Dow announced its alliance with Azelis,…

Global Smart manufacturing has become a key component of today’s industrial evolution and unlocked unprecedented efficiencies and quality enhancements. Smart Manufacturing expert Eric Whitley outlines the specific benefits of smart manufacturing for the pharmaceutical industry, illustrating these benefits with industry case studies.   Smart manufacturing has entered the world of modern…

Global Eli Lilly recently revealed more than promising clinical trial results for its Alzheimer’s candidate, donanemab, showing that the drug slows Alzheimer’s by as much as 60 percent in mild cases. While safety concerns about the drug remain, Lilly is hoping for an FDA approval by the end of the year.…

USA Founded in 1980 “at the dawn of a biotechnology revolution,” Amgen has held its ground throughout its more than 40-year history with innovative approaches to drug discovery that have led to a number of breakthrough therapies. Chairman and CEO Bob Bradway recently spoke to the Money Maze podcast about the…

LatAm Writing in the July 2023 edition of DIA’s Global Forum magazine, Mariana Abdala of Crystal Research outlines the vast room for improvement in Latin America’s clinical trial output, the region’s fundamentals as a research hotspot, and the strategies in place to bolster its global positioning.   Clinical trials in Latin…

Takeda Japanese-headquartered Takeda has been undergoing a transformation in recent years, becoming the global leader in rare diseases with the acquisition of Shire in 2018 and divesting ‘non-core’ assets in OTC and consumer goods. Here, four country and regional managers that PharmaBoardroom has spoken to in the past 12 months discuss…

USA David H. Crean, Ph.D., Managing Partner at Cardiff Advisory, provides his insights on the potential impact of the US Federal Trade Commission (FTC)’s antitrust policies on biopharmaceutical mergers and acquisitions. Crean expects to see a continuation of 2023’s strong start to M&A and questions whether the FTC’s newly-aggressive approach will…

Brazil The latest pharma news from Brazil, including Daiichi Sankyo’s new plant; Bristol Myers Squibb’s re-entry into Brazil’s cardiology market; the Anvisa approval of HIV prevention drug, cabotegravir; Merck’s gamble on the Brazilian obesity market and Novo Nordisk’s patent extension denial.   Japan’s Daiichi Sankyo invests $80 million to expand Brazilian…

USA Big Pharma has been raging against the US’s Inflation Reduction Act (IRA) ever since it was passed last year. Merck (MSD global) has recently taken its indignation a step further and sued the US government, arguing that the new legislation violates the constitution, but shareholders at the ICCR are not…